Eli Lilly: Buy The GLP-1 Growth Premium

Eli Lilly's tirzepatide-based Mounjaro and Zepbound generate nearly $15 billion in revenue, with year-over-year growth of 91% and 46%, respectively. The analyst assigns LLY a buy rating, arguing that its 25x EV/EBITDA premium is supported by annual sales growth above 20% and expanding free cash flow.

Analysis

The key underwriting question is whether growth converts into durable, profitable supply—not whether demand exists. If manufacturing capacity limits shipments, near-term sales may undershoot demand while competitors and compounded alternatives capture patients; if capacity expands faster than payer access, realized net pricing rather than volume becomes the constraint. Either path can disappoint a premium valuation without reversing the long-run obesity opportunity.

The thesis is also unusually exposed to tirzepatide: slower refill persistence, tighter payer coverage, lower net prices, or stronger competing data from Novo Nordisk would weaken the earnings-duration case. Conversely, evidence that Lilly can add capacity while preserving net price and expanding access would support the premium. Treat the cited valuation and growth claims as the article author's framing, not independently verified market facts.

Days to weeks: the article itself is not a catalyst. Over 1–3 months, monitor Lilly's guidance, supply commentary, prescription-to-revenue conversion, and payer access. Over 6–18 months, manufacturing execution, competitive product launches, and pricing policy matter more than headline prescription growth. The contrarian risk is that investors extrapolate demand into margins and cash flow before those are demonstrated.

Key Decisions for Investors

• Do not add to LLY solely on this bullish commentary. Before initiating or increasing exposure, verify current valuation, positioning, and whether incremental prescription volume is converting into net revenue and cash flow.
• If those checks support the thesis, consider a staged LLY long rather than chasing a single-day move; define the thesis around supply expansion and maintained net pricing, not demand alone.
• Set a 1–3 month alert for guidance or disclosures showing shipment growth without corresponding revenue conversion, weaker payer access, or net-price pressure. Those would challenge the premium-growth thesis and justify reducing exposure.
• Reassess over 6–18 months against manufacturing capacity, patient persistence, and competitive clinical or commercial progress from Novo Nordisk. A material deterioration in any of these would falsify the durable-growth case; improving access with stable pricing would strengthen it.